Familial Chylomicronemia Syndrome clinical trials at UCSF
1 research study open to eligible people
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)
open to eligible people ages 18 years and up
The purpose of the study is to evaluate the efficacy of Olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.
San Francisco, California and other locations